PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

Esco Group acquires AT Medical UAB

 Esco Group to acquire AT Medical UAB, an Esco Ventures portfolio company, to accelerate development of the Esco life sciences ecosystem and delivery of innovative fertility technologies

Esco Group has entered into an agreement to acquire the remaining shares in AT Medical UAB, an Esco Ventures portfolio company.

AT Medical UAB is the developer of innovative IVF medical devices whose products are currently distributed by Esco under the Esco Medical brand. The transaction is expected to close in June 2018.

“We are extremely excited to welcome AT Medical to the Esco family,” commented XQ Lin, Group President & CEO of Esco Group. “This strengthens our commitment to innovation within the fast-growing fertility technologies market, leveraging the Esco Group’s global network to accelerate product development and drive distribution. Furthermore, it is a successful example of Singaporean-European collaboration in the life sciences field.”

The acquisition will bring together two companies committed to innovation as well as standardizing and automating IVF laboratory workflow and processes, enabling the world’s leading IVF centers to achieve better clinical outcomes and patient satisfaction.

Under the terms of the agreement, Esco Micro Pte Ltd, the primary operating entity of Esco Group, will make an undisclosed payment for the remaining shares in AT Medical UAB. The acquisition price represents a ~16X ROI multiple on the first investment Esco made into AT Medical UAB.

SORAINEN is serving as Esco Group’s legal counsel.

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40